Boston Scientific stock price target raised by UBS to $140 on strong growth

Investing.com - UBS raised its price target on Boston Scientific (NYSE:BSX), a $153.9 billion medical device maker, to $140.00 from $135.00 on Thursday, while maintaining a Buy rating on the shares. Currently trading at $103.85, BSX has earned a "GREAT" financial health rating according to InvestingPro analysis.

The price target increase follows Boston Scientific’s quarterly results that showed organic sales and earnings per share growth exceeding both UBS and consensus expectations, with impressive revenue growth of 21.4% year-over-year. The firm highlighted that Boston Scientific continues to benefit from what it considers "the most positive product cycle in all of large-cap MedTech." According to InvestingPro’s comprehensive analysis, which includes 15+ additional insights available to subscribers, the company shows strong momentum despite trading above its Fair Value.

UBS noted that Boston Scientific shares have experienced some rotation away in recent weeks due to macro flows, with the stock trading approximately 8.5% below its 52-week high of $109.50. The firm expressed increased bullishness on the stock given its more reasonable valuation and momentum across key growth areas, a view shared by Wall Street analysts who maintain a strong buy consensus with a rating of 1.32 (where 1 is Strong Buy).

The medical device company’s FARAPULSE product line achieved approximately 63% organic worldwide growth, with U.S. growth accelerating by 40 percentage points on a comp-adjusted basis. International growth for the product also accelerated, though at a more modest mid-single-digit rate.

Boston Scientific’s WATCHMAN device posted 35% organic sales growth, marking the fifth consecutive quarter of growth acceleration as product adoption continues to expand, according to UBS’s analysis.

In other recent news, Boston Scientific reported strong third-quarter 2025 financial results, with worldwide sales exceeding consensus estimates by 2%. The company’s MedSurg and Cardiovascular segments also surpassed expectations, contributing to non-GAAP earnings per share that were 5% higher than analyst estimates. Boston Scientific’s revenue reached $5.065 billion, representing a 20.3% reported growth and 15.3% organic growth, both surpassing the consensus estimate of $4.969 billion. Adjusted earnings per share came in at $0.75, exceeding the consensus estimate of $0.71 and the company’s own guidance range of $0.70-$0.72.

Following these results, several financial firms have adjusted their outlooks on Boston Scientific. Leerink Partners raised its price target to $130 while maintaining an Outperform rating, citing the company’s robust performance. Goldman Sachs also increased its price target to $124, highlighting the company’s potential for growth above its peers. Stifel reiterated its Buy rating with a $125 target, expressing confidence in the company’s double-digit revenue growth outlook for 2026-2028. Additionally, BTIG maintained a Buy rating with a $132 price target, and Evercore ISI raised its target to $113, noting strong performance across various business segments despite concerns in the electrophysiology segment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.